Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world CNS adverse events and management with lorlatinib in ALK-positive advanced NSCLC
ChiCTR2400093310Phase 4Not yet recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lorlatinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Effect of management measures for CNS adverse events after lorlatinib on adverse events. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400093310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093310.